Market closed
RenovoRx/$RNXT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About RenovoRx
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Ticker
$RNXT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
10
Website
RenovoRx Metrics
BasicAdvanced
$39M
-
-$0.40
1.12
-
Price and volume
Market cap
$39M
Beta
1.12
52-week high
$1.10
52-week low
$0.75
Average daily volume
107K
Financial strength
Current ratio
4.101
Quick ratio
3.77
Long term debt to equity
4.734
Total debt to equity
6.208
Management effectiveness
Return on assets (TTM)
-143.08%
Return on equity (TTM)
-1,192.69%
Valuation
Price to revenue (TTM)
546.632
Price to book
5.66
Price to tangible book (TTM)
5.66
Price to free cash flow (TTM)
-2.572
Growth
Earnings per share change (TTM)
-60.20%
3-year earnings per share growth (CAGR)
-31.14%
RenovoRx News
AllArticlesVideos
Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial
Business Wire·1 week ago
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th
Business Wire·1 month ago
RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for RenovoRx stock?
RenovoRx (RNXT) has a market cap of $39M as of May 09, 2025.
What is the P/E ratio for RenovoRx stock?
The price to earnings (P/E) ratio for RenovoRx (RNXT) stock is 0 as of May 09, 2025.
Does RenovoRx stock pay dividends?
No, RenovoRx (RNXT) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next RenovoRx dividend payment date?
RenovoRx (RNXT) stock does not pay dividends to its shareholders.
What is the beta indicator for RenovoRx?
RenovoRx (RNXT) has a beta rating of 1.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.